Vertebral Marrow Attention Trial (VMAT)
The purpose of this study is to see whether designing radiation to spare the vertebral bone marrow can limit the rates of lymphopenia during standard of care chemoradiation therapy and in the time to count recovery in the ensuing weeks. Secondary endpoints will examine whether this leads to improved disease control whether this is predictive of improved clinical outcomes such as rates of local recurrence (LR), metastasis free survival (MFS), overall survival (OS), and progression free survival (PFS) which will be followed prospectively up to 5 years.
Checked against the public recordLast updated Oct 30, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Interventions being studied
- Other: Evidence-based radiation dose limitation to the vertebral bone marrow
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Adult patient \> 18 years * Patients with AJCC (American Joint Committee on Cancer) 8 T1-T4, N1-N3, M0 stage IIIA-IIIC NSCLC (non small cell lung cancer) * Patients with oligometastatic disease stage IV, M1 disease, in which definitive concurrent chemoradiotherapy to the thorax is planned * CBC/CMP within these limits * Absolute lymphocyte count\>500/ml * Hemoglobin\>8 g/dL * AST (aspartate aminotransferase)/ALT (alanine transaminase) \<2.5 times of ULN * Eastern Cooperative Oncology Group (ECOG) 0-2 Exclusion Criteria: * History of thoracic irradiation * History of palliative radiation for the current malignancy under consideration * Patients not being treated with definitive standard of care to the chest * History of bone marrow disease and or leukemia * History of prior cytotoxic chemotherapy for a disease other than for the current malignancy * Polymetastatic disease, defined here as ≥3 or more extrathoracic metastases * Administration of concurrent immunotherapy during radiation therapy, either as part of another clinical trial or otherwise
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Vanderbilt-Ingram Service for Timely AccessNashville, Tennessee
- Mays Cancer Center, UT Health San AntonioSan Antonio, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 30, 2024. Always confirm current availability with the study team.